Corporate Banner
Satellite Banner
Medicinal Chemistry
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Rhenovia Pharma Recognized as the World Leader in Biosimulation of CNS

Published: Monday, May 20, 2013
Last Updated: Monday, May 20, 2013
Bookmark and Share
In 2013, the company is preparing to gather a second round of EUR 2.5 million to accelerate its development.

Rhenovia Pharma has announced that it has had its position confirmed as world leader in the field of biosimulation for research into drugs for treating diseases of the central nervous system.

Confirmation was received from the “Global Biosimulation Technology Market (2012-2017)” study by the independent company MarketsandMarkets (USA), published in November 2012.

The recognition of Rhenovia’s global leadership crowns the first phase of the development plan for the company, which will now accelerate its growth.

After the first round of seed funding of EUR 350,000 in 2009, Rhenovia is preparing a second round of investment to support its development and reinforce its position as world leader. The company plans to recruit around 20 new employees in France over the next five years.

Rhenovia also plans to accelerate its international development by strengthening its American subsidiary, founded in Boston in 2012, where it plans to hire around ten new employees.

The company also intends to create new direct operations or partnerships in Europe, Asia and Latin America.

“We are delighted to have received this recognition from MarketsandMarkets of our status as leader in the field of biosimulation for the CNS. Today, biosimulation is an indispensable technology within the pharmaceutical industry and Rhenovia is becoming the preferred partner, with its ability to support all market participants by providing services or research and development partnerships,” said Dr. Serge Bischoff, CEO of Rhenovia.

Dr. Bischoff continued, “The results of this study have provided further encouragement to us in continuing to develop this promising technology, which can not only be used in numerous areas of human healthcare, but also in the food and defense industries. The founders, the employees and even the shareholders of Rhenovia are driven by strongly shared passion and ethics, placing people at the heart of the company’s development strategy.”

Rhenovia has developed a unique modeling technology, which makes it possible to reproduce on a computer the cellular and molecular mechanisms of the brain and nervous transmission.

The company uses its technology to create computer simulations of the condition of healthy patients or patients affected by pathologies of the nervous system, such as Alzheimer’s disease, Parkinson’s disease, epilepsy, schizophrenia or depression.

These simulations are used to predict the efficacy and toxicity of molecules and combinations of molecules, without having to resort to lengthy and expensive in vitro/in vivo experiments.

Within the context of services and R&D partnerships, Rhenovia’s bioinformatics simulations allow biotech and pharmaceutical companies to shorten the development time for new drugs, whilst also reducing risks and costs.

They also aim to anticipate any lack of efficacy or side effects within the products tested and thus to support health authorities in their preclinical and clinical authorization decisions.

Scientifically, the relevance of Rhenovia’s biosimulation technology has been demonstrated by the discovery in 2012 of a new candidate drug for Huntington’s disease, the identification of toxicity or side effects of candidate drugs and by a number of other research projects relating to rare diseases, defense and the food industry.

The global market for biosimulation in drug R&D is estimated to be USD 432 million (EUR 324 million) and is expected to reach USD 1.2 billion by 2017 (EUR 900 million), thanks to an annual growth of 18.5 per cent.

Biosimulation used in the preclinical and clinical phases represents 60 per cent of the total market (2011 figures – MarketsandMarkets study).

“Biosimulation is expected to progress significantly over the next ten years, under the impetus of advances in the fields of systems biology and computational biology,” said the analyst in charge of the study at MarketsandMarkets. “Pharmaceutical companies have now realized the importance of biosimulation in relation to other technologies, from the perspective of R&D that is increasingly based on translational research.”


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,500+ scientific posters on ePosters
  • More than 5,000+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Rhenovia Pharma Opens First US Office
Deployment will widen use of biosimulation technology.
Friday, January 27, 2012
Rhenovia Enters into a Strategic Alliance with Portmann Instruments for Marketing its Biosimulation Services in Switzerland
The two companies have signed a strategic agreement covering the promotion of Rhenovia’s drug optimization technologies on the Swiss and German markets.
Thursday, May 26, 2011
Rhenovia Signs Two-year EUR 500,000 Partnership with AFM for Diseases of the Nervous System
Agreement will accelerate development of Rhenovia’s technology and enable AFM to explore new avenues for the treatment of neurological diseases.
Friday, December 10, 2010
Scientific News
Designing Drugs with a Whole New Toolbox
Researchers develop methods to design small, targeted proteins with shapes not found in nature.
Small Molecules Lead to a Big Change in Reaction Outcomes
Scientists have changed the behaviour of a group of molecules involved in carbon-oxygen bond synthesis.
Targeting Fat to Treat Cancer
Researchers develop novel cancer treatment that halts fat synthesis in cells, stunting tumors.
Hyperstable Peptides for 'On-Demand' Drugs
These small molecules can fold into different conformations that could allow for greater flexibility in precision drug design
Drug Leads Identified to Combat Heart Disease
Using three supercomputers, researchers surveyed protein structures through accelerated molecular dynamics.
Accelerating the Path to Molecules for Medicine
Researchers convert carbon-hydrogen bonds into nitriles - converting organic molecules into components of medicines.
New Hope for Zika Treatment Found in Large-Scale Screen of Existing Drugs
Johns Hopkins researchers join collaborative group to screen 6,000 existing drugs in hopes of finding treatments for Zika Virus infection
Game Changing Antibacterial Drug Research
Researchers publish report on the synthesis of a newly discovered “game-changing” antibiotic, Teixobactin.
New Way of Displaying 3D Molecular Structures
Metal-organic frameworks provide a new platform for solving the structure of hard-to-study samples.
Agent Blocks Pain Without Morphine's Side Effects
Scientists have synthesised a molecule with specific pain-relief properties and has shown its efficacy in mice.
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,500+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
5,000+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!